Skip to Main content Skip to Footer content
Understanding Central Nervous System Tumors
Back to Articles
Articles National Cancer Institute September 25, 2026
Share This Article:

Central Nervous System Tumors

Discover World-Class Cancer Care Close to Home

FCS has a national reputation for excellence that is reflected in exceptional and compassionate patient care, innovative clinical research, cutting-edge technologies, and advanced treatments. With nearly 100 locations, FCS serves patients throughout Florida. we are committed to providing world-class cancer care in community-based settings close to home.

FCS physicians and leaders share insights on cancer care policy, innovation, access and patient-centered oncology at the 2026 PCOC conference.
FCS Contributes to Shaping Future Cancer Care Policy & Innovations At Patient-Centered Oncology Care® Conference

FCS physicians and leaders share insights on cancer care policy, innovation, access and patient-centered oncology at the 2026 PCOC conference.

Hereditary Cancer Spotlight: Ovarian Cancer — approximately 10-20% of ovarian cancer cases diagnosed are hereditary, caused by a pathogenic inherited mutation
Hereditary Cancer Spotlight: Ovarian Cancer

Approximately 10-20% of ovarian cancers are linked to inherited gene mutations. FCS explains germline testing, risk syndromes and who should be tested.

New FDA-approved drug offers hope for advanced pancreatic cancer patients – Florida Cancer Specialists & Research Institute
New FDA-Approved Drug Offers Hope for Advanced Pancreatic Cancer Patients

Daraxonrasib nearly doubled survival vs. chemotherapy in advanced pancreatic cancer. See how FCS early-phase trials helped lead to its FDA approval.

Hassan Hasanein, MD, who joined FCS through a trusted physician referral
A Trusted Referral Leads to the Right Fit at FCS

Discover how a physician referral brought oncologist Hassan Hasanein, MD, to Florida Cancer Specialists & Research Institute and why FCS was his top choice.

Share This Article: